Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Change in Accured Expenses: 2011-2025

Historic Change in Accured Expenses for Abeona Therapeutics (ABEO) over the last 10 years, with Sep 2025 value amounting to $1.0 million.

  • Abeona Therapeutics' Change in Accured Expenses rose 1367.09% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 271.55%. This contributed to the annual value of $1.5 million for FY2024, which is 26.16% down from last year.
  • As of Q3 2025, Abeona Therapeutics' Change in Accured Expenses stood at $1.0 million, which was down 72.79% from $3.7 million recorded in Q2 2025.
  • Abeona Therapeutics' Change in Accured Expenses' 5-year high stood at $5.3 million during Q4 2021, with a 5-year trough of -$4.4 million in Q1 2022.
  • Over the past 3 years, Abeona Therapeutics' median Change in Accured Expenses value was $1.0 million (recorded in 2025), while the average stood at $531,818.
  • As far as peak fluctuations go, Abeona Therapeutics' Change in Accured Expenses plummeted by 378.19% in 2022, and later surged by 1,367.09% in 2025.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Change in Accured Expenses stood at $5.3 million in 2021, then crashed by 80.75% to $1.0 million in 2022, then climbed by 25.76% to $1.3 million in 2023, then surged by 33.46% to $1.7 million in 2024, then spiked by 1,367.09% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $3.7 million for Q2 2025, and -$2.4 million during Q1 2025.